Kulkarni Samarth — SEC Form 4 filings
SEC reporting owner CIK 1682019. 39 Form 4 filings on record with FilingPulse; latest filed 2026-06-29.
Transaction summary — filings shown
Covers all 39 filings on record, filed 2024-01-18 to 2026-06-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 33 legs across 22 filings — 456,376 shares, $27,383,015 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 67.
- Largest priced transaction: sale of 60,000 shares @ $60.23 ($3,613,800) in CRISPR Therapeutics AG, filed 2026-01-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | Chief Executive Officer, Director | 30 | — | 33 legs · 456,376 sh · $27,383,015 | 54 |
| Centessa Pharmaceuticals plc (CNTA) | Director | 3 | — | — | 7 |
| Black Diamond Therapeutics, Inc. (BDTX) | Director | 3 | — | — | 3 |
| Oruka Therapeutics, Inc. (ORKA) | Director | 2 | — | — | 2 |
| Repare Therapeutics Inc. (RPTX) | Director | 1 | — | — | 1 |
Form 4 filings — Kulkarni Samarth
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Centessa Pharmaceuticals plc (CNTA) | Disposition to issuer (D): 208,474 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 48,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2026-06-03 | 4 | Oruka Therapeutics, Inc. (ORKA) | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 19,687 · Sale (S): 10,020 @ $46.78 · Grant/award (A): 114,249 (derivative) @ $0 · Grant/award (A): 81,875 (derivative) @ $0 · Option exercise (M): 19,687 (derivative) | EDGAR |
| 2026-03-17 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 20,625 · Sale (S): 10,349 @ $48.26 · Option exercise (M): 20,625 (derivative) | EDGAR |
| 2026-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 19,250 · Sale (S): 9,798 @ $52.80 · Option exercise (M): 19,250 (derivative) | EDGAR |
| 2026-02-20 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 13,250 · Sale (S): 6,967 @ $52.58 · Option exercise (M): 13,250 (derivative) | EDGAR |
| 2026-01-22 | 4 | CRISPR Therapeutics AG (CRSP) | Sale (S): 21,433 @ $51.61 · Sale (S): 8,567 @ $52.10 · Sale (S): 60,000 @ $60.23 | EDGAR |
| 2025-12-22 | 4 | CRISPR Therapeutics AG (CRSP) | Gift (G): 30,000 @ $0 | EDGAR |
| 2025-10-20 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 100,000 · Sale (S): 50,895 @ $67.91 · Option exercise (M): 100,000 (derivative) | EDGAR |
| 2025-10-15 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 8,334 · Sale (S): 4,242 @ $66.60 · Option exercise (M): 8,334 (derivative) | EDGAR |
| 2025-10-03 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
| 2025-09-19 | 4 | CRISPR Therapeutics AG (CRSP) | Gift (G): 6,000 @ $0 | EDGAR |
| 2025-08-19 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 25,000 · Sale (S): 13,081 @ $58.15 · Option exercise (M): 25,000 (derivative) | EDGAR |
| 2025-06-24 | 4 | Centessa Pharmaceuticals plc (CNTA) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Oruka Therapeutics, Inc. (ORKA) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 19,688 · Sale (S): 10,031 @ $41.23 · Option exercise (M): 19,688 (derivative) | EDGAR |
| 2025-03-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 110,000 (derivative) @ $0 · Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 19,250 · Sale (S): 9,973 @ $42.42 · Option exercise (M): 9,000 · Sale (S): 4,462 @ $43.32 · Option exercise (M): 19,250 (derivative) · Option exercise (M): 9,000 (derivative) | EDGAR |
| 2025-02-21 | 4 | CRISPR Therapeutics AG (CRSP) | Sale (S): 18,360 @ $55.20 | EDGAR |
| 2025-02-19 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 13,250 · Sale (S): 11,640 @ $55.05 · Sale (S): 6,928 @ $52.80 · Option exercise (M): 13,250 (derivative) | EDGAR |
| 2024-12-27 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 13,751 @ $16.21 · Option exercise (M): 13,751 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | CRISPR Therapeutics AG (CRSP) | Sale (S): 15,000 @ $55.10 | EDGAR |
| 2024-11-13 | 4 | CRISPR Therapeutics AG (CRSP) | Sale (S): 23,121 @ $55.43 · Sale (S): 6,879 @ $56.27 | EDGAR |
| 2024-10-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 8,333 · Sale (S): 4,293 @ $46.28 · Option exercise (M): 8,333 (derivative) | EDGAR |
| 2024-08-12 | 4 | CRISPR Therapeutics AG (CRSP) | Gift (G): 100,000 @ $0 | EDGAR |
| 2024-06-27 | 4 | Centessa Pharmaceuticals plc (CNTA) | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 19,582 @ $19.12 · Sale (S): 18,378 @ $59.88 · Sale (S): 1,204 @ $60.40 · Option exercise (M): 19,582 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 105,000 (derivative) @ $0 · Grant/award (A): 78,750 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 20,000 @ $19.12 · Sale (S): 10,613 @ $71.97 · Sale (S): 9,387 @ $73.06 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 19,250 · Sale (S): 9,802 @ $78.26 · Option exercise (M): 9,000 · Sale (S): 4,583 @ $74.44 · Option exercise (M): 19,250 (derivative) · Option exercise (M): 9,000 (derivative) | EDGAR |
| 2024-02-21 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 13,250 · Sale (S): 6,370 @ $79.67 · Option exercise (M): 13,250 (derivative) | EDGAR |
| 2024-02-16 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 20,000 @ $19.12 · Sale (S): 12,949 @ $79.94 · Sale (S): 5,951 @ $81.04 · Sale (S): 1,100 @ $81.66 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 50,000 @ $19.12 · Sale (S): 49,300 @ $60.50 · Sale (S): 700 @ $61.10 · Option exercise (M): 50,000 (derivative) | EDGAR |
| 2024-01-18 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 20,000 @ $19.12 · Sale (S): 20,000 @ $62.50 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1682019 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →